CBSC (Cardiac Biotech Solutions) Liabilities-to-Assets : 13.17 (As of Jun. 2025)

Author:

Vera Yuan

Director of Data and Quant Analytics at GuruFocus

Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.

View Profile →

Reviewed by:

Charlie Tian

Founder & CEO of GuruFocus

Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

View Profile →

What is Cardiac Biotech Solutions Liabilities-to-Assets?

Cardiac Biotech Solutions CBSC Liabilities-to-Assets is 13.17 as of Jun. 2025.

Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities, calculated as total liabilities divided by total asset. Cardiac Biotech Solutions's Total Liabilities for the quarter that ended in Jun. 2025 was $2.28 Mil. Cardiac Biotech Solutions's Total Assets for the quarter that ended in Jun. 2025 was $0.17 Mil. Therefore, Cardiac Biotech Solutions's Liabilities-to-Assets Ratio for the quarter that ended in Jun. 2025 was 13.17.

Cardiac Biotech Solutions (OTCPK:CBSC) Liabilities-to-Assets Explanation

Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities. It can vary greatly across different industries, as they have different capital structure. A high Liabilities-to-Assets ratio (more leveraged) suggests that the company might have potential solvency problems, or even a signal of financial distress. Conversely, a low Liabilities-to-Assets ratio usually indicates a healthy financial situation. However, it may also suggest that the company is not expanding or not making good use of debt.

Cardiac Biotech Solutions Liabilities-to-Assets Related Terms

Cardiac Biotech Solutions Liabilities-to-Assets Historical Data

* Premium members only.

The historical data trend for Cardiac Biotech Solutions's Liabilities-to-Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cardiac Biotech Solutions Liabilities-to-Assets Chart

Cardiac Biotech Solutions Annual Data

Trend

Mar21

Mar22

Mar23

Mar24

Mar25

Liabilities-to-Assets

1.61

0.25

2.24

3.14

12.73

Cardiac Biotech Solutions Quarterly Data
	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Mar25	Jun25
Liabilities-to-Assets	Get a 7-Day Free Trial												3.14	5.68	5.18	12.73	13.17

CBSC vs LUCY, NXGL, MHUAF: Liabilities-to-Assets Comparison

For the Medical Instruments & Supplies subindustry, Cardiac Biotech Solutions's Liabilities-to-Assets, along with its competitors' market caps and Liabilities-to-Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cardiac Biotech Solutions Liabilities-to-Assets vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Cardiac Biotech Solutions's Liabilities-to-Assets distribution charts can be found below:

* The bar in red indicates where Cardiac Biotech Solutions's Liabilities-to-Assets falls into.

Save Embed

Cardiac Biotech Solutions Liabilities-to-Assets Calculation

Liabilities-to-Assets ratio measures the portion of the total liabilities to the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Liabilities-to-Assets ratio is calculated by dividing total liabilities by total asset.

Cardiac Biotech Solutions's Liabilities-to-Assets Ratio for the fiscal year that ended in Mar. 2025 is calculated as:

Liabilities-to-Assets (A: Mar. 2025 )	=	Total Liabilities	/	Total Assets
	=	2.125	/	0.167
	=	12.72

Cardiac Biotech Solutions's Liabilities-to-Assets Ratio for the quarter that ended in Jun. 2025 is calculated as

Liabilities-to-Assets (Q: Jun. 2025 )	=	Total Liabilities	/	Total Assets
	=	2.279	/	0.173
	=	13.17

Frequently Asked Questions Learn more about Liabilities-to-Assets →

What does a Liabilities-to-Assets of 13.17 mean?

Cardiac Biotech Solutions (CBSC) has a Liabilities-to-Assets of 13.17 as of Jun. 2025. Liabilities-to-Assets equals total liabilities divided by total assets. It measures financial leverage. View historical data on Cardiac Biotech Solutions and its competitors.

Is Cardiac Biotech Solutions' Liabilities-to-Assets too high?

Cardiac Biotech Solutions' current Liabilities-to-Assets is 13.17.

How does Cardiac Biotech Solutions' Liabilities-to-Assets compare to LUCY and NXGL?

Cardiac Biotech Solutions' Liabilities-to-Assets of 13.17 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Liabilities-to-Assets for a Medical Devices & Instruments company?

A good Liabilities-to-Assets depends on the Medical Devices & Instruments industry context. However, Liabilities-to-Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Liabilities-to-Assets mean?

A high Liabilities-to-Assets can signal that a stock is expensive relative to its fundamentals. Liabilities-to-Assets equals total liabilities divided by total assets. It measures financial leverage. View historical data on Cardiac Biotech Solutions and its competitors. Cardiac Biotech Solutions's current Liabilities-to-Assets is 13.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Cardiac Biotech Solutions stock overvalued right now?

Cardiac Biotech Solutions (CBSC) has a current Liabilities-to-Assets of 13.17. The current Liabilities-to-Assets is 13.17. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Liabilities-to-Assets calculated?

Liabilities-to-Assets is calculated from a company's financial statements. For Cardiac Biotech Solutions (CBSC), the current Liabilities-to-Assets is 13.17 as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cardiac Biotech Solutions Business Description

Industry Healthcare Medical Devices & Instruments

Comparable Companies LUCY NXGL MHUAF RSCF GCTK YBGJ FEMY ECIA UEEC BNGO ISRG XPAR:EL TSE:7741 BDX XSWX:ALC MDLN RMD WST XSWX:STMN TSE:4543

Address 10845 Griffith Peak Drive, Suite 200, Las Vegas, NV, USA, 89135

Website https://www.cbscientificinc.com

Cardiac Biotech Solutions Inc, through its U.S. and international subsidiaries, provides products and services in the ambulatory non-invasive cardiac monitoring space. The FDA and CE cleared EKG devices, interactive cloud-based acquisition software, and smartphone apps for both iOS and Android platforms, provide improved compliance for patients at risk of abnormal heart rhythms as well as more accurate information for physicians.